PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-143.14%
Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.
5.86%
Positive operating income growth while AGEN is negative. John Neff might view this as a competitive edge in operations.
-142.73%
Both companies face declining net income. Martin Whitman would suspect external pressures or flawed business models in the space.
-120.58%
Both companies exhibit negative EPS growth. Martin Whitman would consider sector-wide issues or an unsustainable business environment.
-120.58%
Both face negative diluted EPS growth. Martin Whitman would suspect an industry or cyclical slump with heightened share issuance across the board.
10.21%
Share count expansion well above AGEN's 14.56%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
10.21%
Diluted share count expanding well above AGEN's 14.56%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
9.39%
Positive OCF growth while AGEN is negative. John Neff would see this as a clear operational advantage vs. the competitor.
9.37%
Positive FCF growth while AGEN is negative. John Neff would see a strong competitive edge in net cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-56347.73%
Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.
-5186.83%
Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.
-34380.15%
Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.
-67208.18%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-8163.79%
Both exhibit negative net income/share growth over five years. Martin Whitman would suspect a challenging environment for the entire niche.
-121.82%
Both companies show negative 3Y net income/share growth. Martin Whitman suspects macro or sector-specific headwinds in the short run.
31995.75%
10Y equity/share CAGR above 1.5x AGEN's 158.84%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.
9371.92%
5Y equity/share CAGR above 1.5x AGEN's 1945.60%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.
10880.98%
3Y equity/share CAGR above 1.5x AGEN's 3192.94%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
31.29%
Asset growth at 50-75% of AGEN's 53.52%. Martin Whitman questions if the firm is lagging expansions or if the competitor invests more aggressively.
28.45%
Under 50% of AGEN's 64.53%. Michael Burry raises concerns about the firm’s ability to build intrinsic value relative to its rival.
-51.38%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
-5.21%
Our R&D shrinks while AGEN invests at 168.69%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-6.73%
We cut SG&A while AGEN invests at 46.09%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.